Reversal Agents for the Direct Factor Xa Inhibitors: Biochemical Mechanisms of Current and Newly Emerging Therapies.

Seminars in Thrombosis and Hemostasis
Mark SchreuderMettine H A Bos

Abstract

The direct oral anticoagulants targeting coagulation factor Xa or thrombin are widely used as alternatives to vitamin K antagonists in the management of venous thromboembolism and nonvalvular atrial fibrillation. In case of bleeding or emergency surgery, reversal agents are helpful to counteract the anticoagulant therapy and restore hemostasis. While idarucizumab has been established as an antidote for the direct thrombin inhibitor dabigatran, reversal strategies for the direct factor Xa inhibitors have been a focal point in clinical care over the past years. In the absence of specific reversal agents, the off-label use of (activated) prothrombin complex concentrate and recombinant factor VIIa have been suggested as effective treatment options during inhibitor-induced bleeding complications. Meanwhile, several specific reversal agents have been developed. In this review, an overview of the current state of nonspecific and specific reversal agents for the direct factor Xa inhibitors is provided, focusing on the biochemistry and mechanism of action and the preclinical assessment of newly emerging therapies.

References

Aug 5, 1993·Journal of Molecular Biology·K PadmanabhanW Kisiel
Dec 24, 1997·British Journal of Haematology·D M MonroeH R Roberts
Oct 26, 1999·Vox Sanguinis·P L TurecekH P Schwarz
Dec 12, 2002·Chemical Reviews·Lizbeth Hedstrom
Aug 18, 2004·Nature Structural & Molecular Biology·Wei LiJames A Huntington
Sep 24, 2004·Haemophilia : the Official Journal of the World Federation of Hemophilia·P L TurecekH P Schwarz
Sep 1, 2009·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN RE-LY Steering Committee and Investigators
Jan 26, 2011·American Journal of Hematology·S B DeitelzweigK L Schulman
Feb 15, 2011·Journal of Thrombosis and Thrombolysis·Pancras C WongDonglu Zhang
Aug 13, 2011·The New England Journal of Medicine·Manesh R PatelUNKNOWN ROCKET AF Investigators
Oct 25, 2011·Nature Biotechnology·Lacramioara IvanciuRodney M Camire
Apr 12, 2012·Haematologica·Raphaël Marlu, Benoît Polack
Oct 23, 2012·Journal of Cellular Physiology·Ahmed A RehmanFahim H Khan
Jan 24, 2013·Stroke; a Journal of Cerebral Circulation·Wei ZhouRoland Veltkamp
Jul 3, 2013·The New England Journal of Medicine·Giancarlo AgnelliUNKNOWN AMPLIFY Investigators
Dec 19, 2013·Circulation·Sumeet S ChughChristopher J L Murray
Jan 30, 2014·Hospital Pharmacy·Dennis J CadaDanial E Baker
Sep 3, 2014·Thrombosis Research·Abdel-Baset HalimJeanne Mendell
Nov 6, 2014·The New England Journal of Medicine·Jack E AnsellJames C Costin
Mar 13, 2015·Thrombosis and Haemostasis·Georges JourdiBernard Le Bonniec
Jun 17, 2015·International Journal of Toxicology·Dexter W SullivanSolomon Steiner
Jun 23, 2015·European Journal of Haematology·Antonio Gómez-OutesEmilio Vargas-Castrillón

❮ Previous
Next ❯

Citations

Apr 2, 2021·Seminars in Thrombosis and Hemostasis·Emmanuel J Favaloro
Dec 29, 2020·Seminars in Thrombosis and Hemostasis·Sam Schulman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Related Papers

Evidence-based Medicine
Kamrouz Ghadimi, Ian J Welsby
Best Practice & Research. Clinical Haematology
Ammar Majeed, Sam Schulman
© 2021 Meta ULC. All rights reserved